Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Pediatric Epilepsy Trial in Subjects 1-24 Months

ClinicalTrials.gov ID: NCT00043875

Public ClinicalTrials.gov record NCT00043875. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:27 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics and Efficacy of Lamictal in Pediatric Age Subjects (1-24 Months)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is being conducted to evaluate the effectiveness and safety of LAMICTAL added to the current therapy of pediatric patients age 1-24 months old with partial seizures. The medication used in this study has been approved by FDA for the adjunctive treatment of partial seizures in patients 2 years and older.

Study identification

NCT ID
NCT00043875
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
177 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
1 Month to 24 Months
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2000 (Type not available)
Primary completion
Nov 2003 (Actual)
Completion
Nov 2003 (Actual)
Last update posted
Sep 15, 2016

2000 – 2003

United States locations

U.S. sites
34
U.S. states
19
U.S. cities
32
Facility City State ZIP Site status
GSK Investigational Site Tucson Arizona 85712 —
GSK Investigational Site Little Rock Arkansas 72202 —
GSK Investigational Site Los Angeles California 90027 —
GSK Investigational Site Los Angeles California 90095 —
GSK Investigational Site Stanford California 94305-5235 —
GSK Investigational Site Denver Colorado 80218 —
GSK Investigational Site Washington D.C. District of Columbia 20010 —
GSK Investigational Site Jacksonville Florida 32207 —
GSK Investigational Site Miami Florida 33155-3009 —
GSK Investigational Site Orlando Florida 32835 —
GSK Investigational Site Tallahassee Florida 32308 —
GSK Investigational Site Tampa Florida 33607-6350 —
GSK Investigational Site Atlanta Georgia 30342 —
GSK Investigational Site Augusta Georgia 30912 —
GSK Investigational Site Lexington Kentucky 40536-0284 —
GSK Investigational Site Saint Paul Minnesota 55102-2383 —
GSK Investigational Site Kansas City Missouri 64108 —
GSK Investigational Site Cherry Hill New Jersey 8034 —
GSK Investigational Site Syracuse New York 13210 —
GSK Investigational Site Chapel Hill North Carolina 27599 —
GSK Investigational Site Raleigh North Carolina 27607 —
GSK Investigational Site Akron Ohio 44308-1062 —
GSK Investigational Site Cleveland Ohio 44106 —
GSK Investigational Site Columbus Ohio 43205 —
GSK Investigational Site Portland Oregon 97227 —
GSK Investigational Site Portland Oregon 97239 —
GSK Investigational Site Pittsburgh Pennsylvania 15213-2583 —
GSK Investigational Site Nashville Tennessee 37212 —
GSK Investigational Site Dallas Texas 75230 —
GSK Investigational Site Fort Worth Texas 76104 —
GSK Investigational Site Houston Texas 77030 —
GSK Investigational Site Charlottesville Virginia 22908 —
GSK Investigational Site Norfolk Virginia 23510 —
GSK Investigational Site Richmond Virginia 23298 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00043875, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 15, 2016 · Synced Nov 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00043875 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →